Supplementary Table 1. Number of randomly assigned and eligible subjects to three interventions by *H. pylori* infection status in 1994

In	tervention	No. of subjects	No. of eligible					
H. pylori treatment	Garlic	Vitamin	randomly assigned	subjects				
H. pylori seropositive subjects in 1994								
A	A	A	286	283				
A	A	P	285	283				
A	P	A	286	281				
A	P	P	285	283				
P	A	A	285	279				
P	A	P	286	282				
P	P	A	286	283				
P	P	P	286	284				
Total			2285	2258				
H. pylori seronegative subjects in 1994								
P	A	A	282	274				
P	A	P	281	277				
P	P	A	281	277				
P	P	P	282	279				
Total			1126	1107				

A: active treatment; P: corresponding placebo

Supplementary Table 2. Baseline characteristics of study subjects

Group	H. pylori treatment		Vitamin sup	plementation	Garlic supplementation	
	Active	Placebo	Active	Placebo	Active	Placebo
	(n=1130)	(n=1128)	(n=1677)	(n=1688)	(n=1678)	(n=1687)
Age (Mean \pm SD)	46.8±9.2	46.9±9.2	47.0±9.2	47.1±9.2	47.0±9.2	47.1±9.2
Sex (%)						
Female	50.4	49.7	48.8	48.6	48.8	48.6
Male	49.6	50.3	51.2	51.4	51.2	51.4
Baseline histology (%)						
<severe cag<="" td=""><td>35.0</td><td>35.6</td><td>43.8</td><td>43.1</td><td>43.6</td><td>43.3</td></severe>	35.0	35.6	43.8	43.1	43.6	43.3
Severe CAG/Sup IM	14.3	14.9	12.7	12.8	11.7	13.8
Deep IM	34.8	34.0	29.2	30.0	30.4	28.8
DYS	15.0	15.1	13.5	13.6	13.5	13.6
Missing	1.0	0.4	0.7	0.5	0.7	0.5
Smoking (%)						
No	55.6	56.2	54.5	54.5	54.2	54.8
Yes	41.3	40.5	41.9	42.4	42.1	42.3
Missing	3.1	3.3	3.6	3.1	3.8	2.9
Alcohol drinking (%)						
No	52.4	52.7	51.5	52.8	52.1	52.2
Yes	44.5	44.0	44.9	44.1	44.1	44.9
Missing	3.1	3.3	3.6	3.1	3.8	2.9

CAG, chronic atrophic gastritis; DYS, dysplasia; GC, gastric cancer; IM, intestinal metaplasia; SG, superficial gastritis

Supplementary Table 3. The number of incident gastric cardiac and non-cardiac cancer cases and deaths by three intervention groups^a

	No. of subjects	No. of incident gastric cancers				No. of deaths due to gastric cancer			
Treatment groups		Total No.	Total No. of known gastric cardiac or non- cardiac cancer ^b	No. of gastric cardiac cancer	No. of gastric non- cardiac cancer	Total No.	Total No. of known gastric cardiac or non- cardiac cancer ^b	No. of gastric cardiac cancer	No. of gastric non- cardiac cancer
H. pylori treatment	2258	119	88	11	77	76	60	10	50
Active	1130	41	35	7	28	29	24	7	17
Placebo	1128	78	53	4	49	47	36	3	33
Vitamin	3365	151	106	15	91	94	72	13	59
Active	1677	60	49	5	44	31	26	3	23
Placebo	1688	91	57	10	47	63	46	10	36
Garlic	3365	151	106	15	91	94	72	13	59
Active	1678	69	46	6	40	39	30	6	24
Placebo	1687	82	60	9	51	55	42	7	35

^aEvents that occurred from the date of random assignment (July 23, 1995), to the end of follow-up (December 1, 2017).

^bEvents with the information on gastric cardiac or non-cardiac cancer that occurred from the date of random assignment (July 23, 1995), to the end of follow-up (December 1, 2017).

Supplementary Table 4. The 2-way interactions between interventions on gastric cancer incidence and mortality

		Gastric cancer incide	ence ^a	Gastric cancer mortality ^a					
Subgroups	n/n ^b	OR (95% CI)	P for interaction ^c	n/n ^b	HR (95% CI)	P for interaction ^c			
Baseline H. pylori seropositive participants									
Joint effect of vitamin supplementation and H. pylori eradication									
Placebo	44/549	Reference	0.72	28/549	Reference	0.56			
H. pylori treatment only	25/543	0.50 (0.30 to 0.85)		20/543	0.69 (0.39 to 1.22)				
Vitamin only	32/537	0.69 (0.42 to 1.13)		17/537	0.60 (0.33 to 1.11)				
H. pylori treatment and vitamin	15/543	0.30 (0.16 to 0.55)		9/543	0.31 (0.15 to 0.66)				
Joint effect of garlic supplementation and H. pylori eradication									
Placebo	40/546	Reference	0.52	28/546	Reference	0.52			
H. pylori treatment only	23/546	0.54 (0.31 to 0.92)		16/546	0.55 (0.30 to 1.01)				
Garlic only	36/540	0.93 (0.57 to 1.50)		17/540	0.59 (0.32 to 1.07)				
H. pylori treatment and garlic	17/540	0.38 (0.21 to 0.69)		13/540	0.44 (0.23 to 0.84)				
Joint effect of garlic and vitamin	suppleme	ntation							
Placebo	41/548	Reference	0.15	31/548	Reference	0.20			
Vitamin only	22/544	0.50 (0.29 to 0.87)		13/544	0.41 (0.22 to 0.79)				
Garlic only	28/544	0.66 (0.39 to 1.10)		17/544	0.53 (0.29 to 0.95)				
Vitamin and garlic	25/536	0.59 (0.35 to 1.00)		13/536	0.41 (0.21 to 0.78)				
Baseline H. pylori seronegative participants									
Joint effect of garlic and vitamin supplementation									
Placebo	14/268	Reference	0.08	8/268	Reference	0.73			
Vitamin only	4/271	0.29 (0.09 to 0.90)		2/271	0.28 (0.06 to 1.36)				
Garlic only	6/267	0.43 (0.16 to 1.16)		5/267	0.71 (0.22 to 2.28)				
Vitamin and garlic	7/259	0.51 (0.20 to 1.32)		1/259	0.12 (0.02 to 1.00)				

^aThe fully adjusted analyses were adjusted for baseline histology (<severe CAG, severe CAG/Sup IM,

Deep IM, DYS), age, sex, history of ever using alcohol and history of ever smoking.

^bNumber of subjects with an event divided by total number of subjects within this stratum.

^c*P* values for interactions were calculated by adding the interaction term between two treatments into the regression models, in addition to the indicators of the two treatments being analyzed.